---
title: "Mentari Therapeutics Presents Migraine Drug Pipeline, Targets First Clinical Data in 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304878301.md"
description: "Mentari Therapeutics outlined its migraine drug pipeline, targeting a first-quarter 2027 regulatory filing for candidate MT-002, with Phase 1 data expected by year-end. MT-001 Phase 1 data are anticipated in mid-2027, followed by Phase 2 proof-of-concept data in 2028. The five-program antibody pipeline includes MT-002, which targets both PACAP and CGRP to potentially improve migraine prevention. Approximately $490 million has been raised to support development beyond key milestones."
datetime: "2026-11-09T15:32:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304878301.md)
  - [en](https://longbridge.com/en/news/304878301.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304878301.md)
generator: "portal-rs"
---

# Mentari Therapeutics Presents Migraine Drug Pipeline, Targets First Clinical Data in 2027

-   Mentari Therapeutics targets a first-quarter 2027 regulatory filing for migraine candidate MT-002, with Phase 1 data expected by year-end. \* MT-001 Phase 1 data are expected in mid-2027, followed by initial Phase 2 proof-of-concept data in migraine patients in 2028. \* The five-program antibody pipeline includes MT-002, which targets both PACAP and CGRP to potentially improve migraine prevention. \* About $490 million raised to date supports development beyond key anticipated milestones. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mentari Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MTRI.US](https://longbridge.com/en/quote/MTRI.US.md)

## Related News & Research

- [MTRI: PACAP/CGRP pipeline targets more effective, less frequent migraine prevention](https://longbridge.com/en/news/305818527.md)
- [Mentari Therapeutics' Total Liabilities Rise to $78.61 Million From $10.26 Million at Year-End](https://longbridge.com/en/news/305668280.md)
- [Wedbush initiates coverage of Mentari Therapeutics at Outperform, sets price target at $33](https://longbridge.com/en/news/305469432.md)
- [ADAR1 Capital Management reports acquisition of $34,571.592 in Mentari Therapeutics common shares](https://longbridge.com/en/news/304932745.md)
- [Jefferies initiates coverage of Mentari Therapeutics at Buy, sets price target at $30](https://longbridge.com/en/news/305028486.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**